New Released Report: Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth

" Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth" is the latest addition to MarketResearchReports.Biz industry research reports collection.

​The objective of this report is to define, describe, and forecast the market on the basis of type, application, medical condition, and region. It provides detailed information regarding the major factors influencing the growth of the market. This report also tracks and analyzes competitive developments of the key players in terms of market developments, product portfolios, and financials.

Get Sample Copy Of This Report @ ​https://www.marketresearchreports.biz/sample/sample/235561

GBI Research, the leading business intelligence provider, has released its latest research, “Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 Increasing Uptake of Novel Drug Classes to Drive Market Growth”, which provides insights into type 2 diabetes in the Asia-Pacific (APAC) markets of China, India, Japan and Australia. The report estimates the market size for 2013 and provides a forecast until 2020, and covers disease epidemiology, treatment algorithms, and treatment use patterns. It also provides in-depth analysis of the pipeline molecules, clinical trial failure rates, and recent deals. The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research’s team of industry experts.
In 2013, the value of the type 2 diabetes therapeutics market in APAC countries was an estimated $6.5 billion, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7.1% between 2013 and 2020 to $10.5 billion. This strong growth is due to the anticipated approval of products in relatively novel treatment classes, such as Glucagon-Like Peptide-1 (GLP-1) agonists, Dipeptidyl Peptidase-4 (DPP-4) inhibitors, and Sodium Glucose Transporter-2 (SGLT-2) inhibitors, as well as the growth of the prevalence population in the APAC region, particularly in India and China.

Scope
The report analyzes the treatment use patterns, market characterization, pipeline analysis and key licensing and co-development deals of the type 2 diabetes in the APAC markets of China, India, Japan, and Australia.It includes
A brief introduction to type 2 diabetes, including its pathophysiology, etiology, diagnosis and treatment algorithms
In-depth analysis of currently marketed drugs for type 2 diabetes, including analysis of their safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing them in terms of safety and efficacy
A comprehensive review of the pipeline for type 2 diabetes, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed by Phase distribution, molecule type, program type, mechanism of action and molecular target
Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
Multi-scenario market forecast data to 2020, taking into account how the market might be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the key developed markets
Discussion of the drivers of and barriers to market growth
In-depth analysis of all licensing and co-development deals that have occurred in the type 2 diabetes market since 2006

View Report @ ​https://www.marketresearchreports.biz/reports/235561/type-diabetes-therapeutics-in-asia-pacific-market-research-reports​

Reasons to buy
The report will enhance your decision-making capability by allowing you to
Understand the type 2 diabetes pipeline and the factors that indicate that it is becoming more innovative
Examine detailed profiles for promising pipeline products and gain an insight into how and with whom they are likely to compete in the market
Follow the trends in type 2 diabetes clinical trial size and duration in relation to industry averages
Assess the potential risk of future developmental programs for type 2 diabetes therapeutics, depending on the mechanism of action, by taking into account the recorded clinical trial failure rates
Examine the growth patterns expected for the type 2 diabetes market over the forecast period and the countries that are expected to contribute the most to this growth, allowing you to devise a more effectively tailored country strategy through an understanding of key drivers and barriers

Accelerate and strengthen your market position by identifying key companies for strategic partnerships

Table of Contents
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Symptoms 8
2.2 Etiology 8
2.3 Pathophysiology 9
2.4 Diagnosis 10
2.5 Epidemiology 12
2.6 Prognosis 13
2.7 Co-Morbidities and Complications 13
2.8 Treatment and Management 14
2.8.1 The Role of Insulin in Type 2 Diabetes 17
2.8.2 Non-Insulin Diabetic Drugs 18
2.8.3 Other Drugs 20

Request For Enquiry @ ​https://www.marketresearchreports.biz/sample/enquiry/235561

3 Marketed Products 21
3.1 Metformin 21
3.2 DPP-4 Inhibitors 22
3.2.1 Januvia (sitagliptin)/Janumet (sitagliptin and metformin), Merck 22
3.2.2 Tradjenta (linagliptin) – Boehringer Ingelheim 23
3.2.3 Onglyza (saxagliptin) – Bristol-Myers Squibb and AstraZeneca 24
3.2.4 Nesina (alogliptin) – Takeda 24
3.2.5 Galvus (vildagliptin) – Novartis 25
3.2.6 Tenelia (teneligliptin) – Daiichi Sankyo and Mitsubishi Tanabe 26
3.3 GLP-1 Agonists 27
3.3.1 Byetta and Bydureon (exenatide) – Bristol-Myers Squibb 27
3.3.2 Victoza (liraglutide) – Novo Nordisk 27
3.3.3 Lyxumia (lixisenatide) – Sanofi 28
3.4 Sulfonylureas 29
3.4.1 Glimepiride 29
3.4.2 Gliclazide 30
3.5 Thiazolidinediones 30
3.5.1 Actos (pioglitazone) – Takeda Pharmaceuticals 30
3.6 Long-Acting Insulins 31
3.6.1 Lantus (insulin glargine) – Sanofi 31
3.6.2 Levemir (insulin detemir) – Novo Nordisk 32
3.7 SGLT Inhibitors 33
3.7.1 Forxiga (dapagliflozin) – Bristol-Myers Squibb 33
3.7.2 Invokana (canagliflozin) – Janssen 33
3.8 Comparative Efficacy and Safety 34​

About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact us

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.